{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11"],"submitter":["Han X"],"pubmed_abstract":["<h4>Background</h4>Phosphodiesterase type 5 inhibitor (PE5i) administration may stimulate the proliferation and survival of melanocytes. However, discrepancies remain regarding the association between PDE5i use and melanoma risk in observational studies in humans.<h4>Aim</h4>To evaluate the association between PDE5i use and melanoma in a meta-analysis.<h4>Materials and methods</h4>Studies were identified by searching the PubMed and Embase databases. A random-effects model was applied to synthesize the data. A stratified study was performed to evaluate the influence of study characteristics on outcomes.<h4>Results</h4>Four prospective cohort studies and three case-control studies with 1,534,615 male participants and 16,053 melanoma cases were incorporated. Patients who received a PDE5i had a significantly increased risk for melanoma (adjusted risk ratio [RR] =1.12, 95% CI =1.03-1.33, <i>P</i>=0.008) with moderate heterogeneity (<i>I</i><sup>2</sup>=54%). Cohort studies (adjusted RR =1.22, 95% CI =1.02-1.46, <i>P</i>=0.03) largely contributed to this result rather than case-control studies. Subsequent stratified analyses revealed that sildenafil was associated with an increased risk of melanoma (adjusted RR =1.26, 95% CI =1.07-1.50, <i>P</i>=0.007), but tadalafil and vardenafil were not. Also, PDE5i use was associated with a significantly increased risk of in situ melanoma (adjusted RR =1.31, 95% CI =1.01-1.69, <i>P</i>=0.04), but not of localized or nonlocalized melanoma.<h4>Conclusion</h4>PDE5i use may be associated with a significantly increased risk for melanoma in men. However, further research is needed to determine whether the association is causative."],"journal":["OncoTargets and therapy"],"pagination":["711-720"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5804137"],"repository":["biostudies-literature"],"pubmed_title":["Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies."],"pmcid":["PMC5804137"],"pubmed_authors":["Xu L","Zheng Y","Dai L","Sun Q","Zhang J","Han X","Han Y","Ma T"],"additional_accession":[]},"is_claimable":false,"name":"Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies.","description":"<h4>Background</h4>Phosphodiesterase type 5 inhibitor (PE5i) administration may stimulate the proliferation and survival of melanocytes. However, discrepancies remain regarding the association between PDE5i use and melanoma risk in observational studies in humans.<h4>Aim</h4>To evaluate the association between PDE5i use and melanoma in a meta-analysis.<h4>Materials and methods</h4>Studies were identified by searching the PubMed and Embase databases. A random-effects model was applied to synthesize the data. A stratified study was performed to evaluate the influence of study characteristics on outcomes.<h4>Results</h4>Four prospective cohort studies and three case-control studies with 1,534,615 male participants and 16,053 melanoma cases were incorporated. Patients who received a PDE5i had a significantly increased risk for melanoma (adjusted risk ratio [RR] =1.12, 95% CI =1.03-1.33, <i>P</i>=0.008) with moderate heterogeneity (<i>I</i><sup>2</sup>=54%). Cohort studies (adjusted RR =1.22, 95% CI =1.02-1.46, <i>P</i>=0.03) largely contributed to this result rather than case-control studies. Subsequent stratified analyses revealed that sildenafil was associated with an increased risk of melanoma (adjusted RR =1.26, 95% CI =1.07-1.50, <i>P</i>=0.007), but tadalafil and vardenafil were not. Also, PDE5i use was associated with a significantly increased risk of in situ melanoma (adjusted RR =1.31, 95% CI =1.01-1.69, <i>P</i>=0.04), but not of localized or nonlocalized melanoma.<h4>Conclusion</h4>PDE5i use may be associated with a significantly increased risk for melanoma in men. However, further research is needed to determine whether the association is causative.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018","modification":"2024-11-10T04:21:36.647Z","creation":"2019-03-26T23:03:08Z"},"accession":"S-EPMC5804137","cross_references":{"pubmed":["29440918"],"doi":["10.2147/OTT.S142637"]}}